Cynata Lifts Placement to ~$750k, Taking Total Raise to ~$1.663m
Cynata Therapeutics (ASX: CYP) said Caravel Securities Pty Ltd (Carasec) has received firm commitments for an additional ~$200,000 of Placement Shares (about 20 million shares), lifting the Placement to ~$750,000 via about 75 million Placement Shares, subject to shareholder approval.
The increase follows the Placement first announced on 4 November 2026, which was for ~$550,000 through about 55 million Placement Shares at $0.01 each. The company said it increased the size of the Placement “in light of interest from sophisticated investors”, and none of the additional ~20 million Placement Shares will be issued to related parties.
The recently completed Entitlement Offer raised $912,953.88 before costs. If shareholders approve the Placement, the combined total across the Placement and Entitlement Offer will be ~$1.663m before costs.
Retail demand for the Entitlement Offer was thin, with shareholders applying for only about 26% of the new shares, leaving underwriter Caravel Securities to absorb the shortfall.
The proceeds of the Placement are intended to give the company greater flexibility to pursue potential transactions to secure rights to new assets. They will also pay for the costs of the Placement and provide further working capital, consistent with the use of funds in the Replacement Prospectus released on 12 October 2026.
Placement terms at a glance
The Placement is priced at $0.01 per share, the same as the Entitlement Offer.
| Component | Amount before costs | Shares | Price per share |
|---|---|---|---|
| Placement (original, 4 November 2026) | ~$550,000 | ~55 million | $0.01 |
| Placement (increase) | ~$200,000 | ~20 million | $0.01 |
| Placement (total) | ~$750,000 | ~75 million | $0.01 |
| Entitlement Offer | ~$913k | n/a | $0.01 |
The attaching options and lead manager terms are:
- One free Attaching Option will be issued for every three Placement Shares, on the same terms as the Entitlement Options issued under the Entitlement Offer.
- The Attaching Options carry an exercise price of $0.02 and an expiry date of 3 May 2029.
- Carasec is lead manager and will receive a placement fee equal to 6% of the amount raised under the Placement, plus Placement Fee Options.
- The number of Placement Fee Options has increased from 6,000,000 to 8,200,000 given the larger Placement, and they carry the same terms as the Attaching Options.
When big ASX news breaks, our subscribers know first
Cymerus clinical trials and IP: where the company stands
Cynata said all material costs relating to recently completed Cymerus™ clinical trials and termination of employee and service provider agreements have been paid, with background in its 6 July 2026 announcement. The company is maintaining its Cymerus™ intellectual property portfolio, including license agreements, patents and cell lines.
The Phase 1/2 NEREID kidney transplant trial of CYP-001 is still ongoing. It is managed and funded by Leiden University Medical Centre (LUMC) in the Netherlands, and enrolment and treatment of the second cohort are complete.
CYP-001 is Cynata’s Cymerus™ induced pluripotent stem cell (iPSC)-derived mesenchymal stromal cell (MSC) product candidate for intravenous use.
- First cohort: three patients each received a single infusion of CYP-001 plus standard treatment. The independent Data and Safety Monitoring Board (DSMB) review announced on 4 December 2025 found no episodes of kidney transplant rejection and no safety concerns.
- Second cohort: three patients each received two infusions of CYP-001 plus standard treatment.
The company said the Cymerus™ platform continues to offer a “genuinely differentiated approach” to manufacturing mesenchymal stromal cells (MSCs) at commercial scale from a single, consistent cell source. The Board is evaluating options for its further development.
Part of the company’s strategy is to identify opportunities to acquire, in-license or otherwise obtain rights to new pharmaceutical or biotechnology assets or development programs. The Board is evaluating a number of opportunities to obtain rights to new assets.
What happens next for Cynata
- A General Meeting of shareholders is expected in January 2027 to seek approval of the Placement (including the Placement Shares and Attaching Options) and the issue of the Placement Fee Options. Details will be communicated “in the coming weeks”.
- A DSMB review of the second NEREID cohort will take place when the final patient in that cohort has been followed up for six weeks after receiving the second infusion of CYP-001. Cynata will announce the results once they are received from LUMC.
Want Alerts Like This on the Biotech Stocks You Follow?
StockWire X Market Intelligence scores every announcement in our coverage for how significant it’s likely to be for investors, and which way it points, then alerts you on the stocks you follow. The first 1,000 founding members lock in 50% off for life: A$247 a year instead of the standard A$495. Join the founding waitlist to claim your spot.